JAK-STAT signaling in cancer: From cytokines to non-coding genome

Cytokine

Volumn 87, Issue , 2016, Pages 26-36

  Pencik, Jan ^a,b,c   Pham, Ha Thi Thanh ^c,d   Schmoellerl, Johannes ^c   Javaheri, Tahereh ^c,d   Schlederer, Michaela ^a,c,d   Culig, Zoran ^e   Merkel, Olaf ^a   Moriggl, Richard ^c,d   Grebien, Florian ^c   Kenner, Lukas ^a,c,d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Division of Nuclear Medicine   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Hematopoietic malignancies; JAK STAT signaling; Non coding RNAs; Prostate cancer; Sarcomas

Indexed keywords

CYTOKINE; JANUS KINASE; LONG UNTRANSLATED RNA; MICRORNA; MICRORNA 155; MICRORNA 18A; MICRORNA 19A; MICRORNA 19B; MICRORNA 216A; MICRORNA 221; MICRORNA 23A; MICRORNA 23B; MICRORNA 9; STAT PROTEIN; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

ARTICLE; CANCER GENETICS; CANCER PROGNOSIS; CARCINOMA; EXTRAOSSEOUS SARCOMA; GENE MUTATION; GENOME ANALYSIS; GERM LAYER; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SARCOMA; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; ANIMAL; GENOME; MALE; METABOLISM; MOUSE; NEOPLASM; PROSTATE TUMOR;

ANIMALS; CYTOKINES; GENOME; HUMANS; JANUS KINASES; MALE; MICE; NEOPLASMS; PROSTATIC NEOPLASMS; RNA, UNTRANSLATED; SARCOMA; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84977575424     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2016.06.017     Document Type: Article

References (203)

1. [1] Wilks, A.F., et al. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol. Cell. Biol. 11 (1991), 2057–2065.
2. [2] Velazquez, L., Fellous, M., Stark, G.R., Pellegrini, S., A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 70 (1992), 313–322, 10.1016/0092-8674(92)90105-L [pii].
3. [3] Levy, D.E., Darnell, J.E. Jr., Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3 (2002), 651–662, 10.1038/nrm909.
4. [4] Haan, C., Kreis, S., Margue, C., Behrmann, I., Jaks and cytokine receptors – an intimate relationship. Biochem. Pharmacol. 72 (2006), 1538–1546, 10.1016/j.bcp.2006.04.013 S0006-2952(06)00227-9 [pii].
5. [5] Ungureanu, D., et al. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat. Struct. Mol. Biol. 18 (2011), 971–976, 10.1038/nsmb.2099.
6. [6] Radtke, S., et al. The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression. J. Biol. Chem. 280 (2005), 25760–25768, 10.1074/jbc.M500822200.
7. [7] Filippakopoulos, P., Muller, S., Knapp, S., SH2 domains: modulators of nonreceptor tyrosine kinase activity. Curr. Opin. Struct. Biol. 19 (2009), 643–649, 10.1016/j.sbi.2009.10.001.
8. [8] Haan, S., et al. Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation. J. Immunol. 180 (2008), 998–1007.
9. [9] Kang, K., Robinson, G.W., Hennighausen, L., Comprehensive meta-analysis of signal transducers and activators of transcription (STAT) genomic binding patterns discerns cell-specific cis-regulatory modules. BMC Genom., 14, 2013, 4, 10.1186/1471-2164-14-4.
10. [10] Xu, D., Qu, C.K., Protein tyrosine phosphatases in the JAK/STAT pathway. Front. Biosci. 13 (2008), 4925–4932.
11. [11] Liu, Y., et al. Protein inhibitor of activated STAT 1 (PIAS1) is identified as the SUMO E3 ligase of CCAAT/enhancer-binding protein beta (C/EBPbeta) during adipogenesis. Mol. Cell. Biol. 33 (2013), 4606–4617, 10.1128/MCB.00723-13.
12. [12] Valentino, L., Pierre, J., JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem. Pharmacol. 71 (2006), 713–721, 10.1016/j.bcp.2005.12.017.
13. [13] Croker, B.A., Kiu, H., Nicholson, S.E., SOCS regulation of the JAK/STAT signalling pathway. Semin. Cell Dev. Biol. 19 (2008), 414–422, 10.1016/j.semcdb.2008.07.010.
14. [14] Kiladjian, J.J., The spectrum of JAK2-positive myeloproliferative neoplasms. Hematol. Am. Soc. Hematol. Educ. Program 2012 (2012), 561–566, 10.1182/asheducation-2012.1.561.
15. [15] Levine, R.L., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7 (2005), 387–397, 10.1016/j.ccr.2005.03.023.
16. [16] Klampfl, T., et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. New England J. Med. 369 (2013), 2379–2390, 10.1056/NEJMoa1311347.
17. [17] Nangalia, J., et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New England J. Med. 369 (2013), 2391–2405, 10.1056/NEJMoa1312542.
18. [18] Rumi, E., et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 123 (2014), 1544–1551, 10.1182/blood-2013-11-539098.
19. [19] Thomas, S.J., Snowden, J.A., Zeidler, M.P., Danson, S.J., The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br. J. Cancer 113 (2015), 365–371, 10.1038/bjc.2015.233.
20. [20] Anderson, J.L., Denny, C.T., Tap, W.D., Federman, N., Pediatric sarcomas: translating molecular pathogenesis of disease to novel therapeutic possibilities. Pediatr. Res. 72 (2012), 112–121, 10.1038/pr.2012.54.
21. [21] Zamo, A., et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 21 (2002), 1038–1047, 10.1038/sj.onc.1205152.
22. [22] Lee, H., et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat. Med. 16 (2010), 1421–1428, 10.1038/nm.2250 nm.2250 [pii].
23. [23] Jarnicki, A., Putoczki, T., Ernst, M., Stat3: linking inflammation to epithelial cancer – more than a “gut” feeling?. Cell Div., 5, 2010, 14, 10.1186/1747-1028-5-14 1747-1028-5-14 [pii].
24. [24] Baffert, F., et al. Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. Mol. Cancer Ther. 9 (2010), 1945–1955, 10.1158/1535-7163.MCT-10-0053.
25. [25] Verstovsek, S., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. New England J. Med. 363 (2010), 1117–1127, 10.1056/NEJMoa1002028.
26. [26] Verstovsek, S., Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. Clin. Cancer Res. 16 (2010), 1988–1996, 10.1158/1078-0432.CCR-09-2836.
27. [27] Harrison, C., JAK inhibitors and myelofibrosis, Einstein and ruxolitinib. Haematologica 100 (2015), 409–411, 10.3324/haematol.2015.124099.
28. [28] Komrokji, R.S., et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood 125 (2015), 2649–2655, 10.1182/blood-2013-02-484832.
29. [29] Wu, J., et al. Long noncoding RNA lncTCF7, induced by IL-6/STAT3 transactivation, promotes hepatocellular carcinoma aggressiveness through epithelial-mesenchymal transition. J. Exp. Clin. Cancer Res., 34, 2015, 116, 10.1186/s13046-015-0229-3.
30. [30] Guo, H., et al. The aspirin-induced long non-coding RNA OLA1P2 blocks phosphorylated STAT3 homodimer formation. Genome Biol., 17, 2016, 24, 10.1186/s13059-016-0892-5.
31. [31] Howe, J.A., et al. Selective small-molecule inhibition of an RNA structural element. Nature 526 (2015), 672–677, 10.1038/nature15542.
32. [32] Velagapudi, S.P., et al. Design of a small molecule against an oncogenic noncoding RNA. Proc. Natl. Acad. Sci. USA 113 (2016), 5898–5903, 10.1073/pnas.1523975113.
33. [33] Jemal, A., et al. Global cancer statistics. CA Cancer J. Clin. 61 (2011), 69–90, 10.3322/caac.20107caac.20107 [pii].
34. [34] Chen, C.D., et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10 (2004), 33–39, 10.1038/nm972.
35. [35] Rathkopf, D.E., et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 31 (2013), 3525–3530, 10.1200/JCO.2013.50.1684.
36. [36] Trotman, L.C., et al. Pten dose dictates cancer progression in the prostate. PLoS Biol., 1, 2003, E59, 10.1371/journal.pbio.0000059.
37. [37] Dhir, R., et al. Stat3 activation in prostatic carcinomas. Prostate 51 (2002), 241–246, 10.1002/pros.10079.
38. [38] Mora, L.B., et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 62 (2002), 6659–6666.
39. [39] Yin, Y., Shen, W.H., PTEN: a new guardian of the genome. Oncogene 27 (2008), 5443–5453, 10.1038/onc.2008.241 onc2008241 [pii].
40. [40] Nardella, C., Clohessy, J.G., Alimonti, A., Pandolfi, P.P., Pro-senescence therapy for cancer treatment. Nat. Rev. Cancer 11 (2011), 503–511, 10.1038/nrc3057.
41. [41] Lin, H.K., et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 464 (2010), 374–379, 10.1038/nature08815nature08815 [pii].
42. [42] Chen, Z., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436 (2005), 725–730, 10.1038/nature03918 nature03918 [pii].
43. [43] Chen, Z., et al. Differential p53-independent outcomes of p19(Arf) loss in oncogenesis. Sci. Signal., 2, 2009, ra44, 10.1126/scisignal.20000532/84/ra44 [pii].
44. [44] Zhang, H., Markadieu, N., Beauwens, R., Erneux, C., Prestwich, G.D., Synthesis and biological activity of PTEN-resistant analogues of phosphatidylinositol 3,4,5-trisphosphate. J. Am. Chem. Soc. 128 (2006), 16464–16465, 10.1021/ja065002j.
45. [45] Courtois-Cox, S., et al. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10 (2006), 459–472, 10.1016/j.ccr.2006.10.003 S1535-6108(06)00289-3 [pii].
46. [46] Michaloglou, C., et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436 (2005), 720–724, 10.1038/nature03890 nature03890 [pii].
47. [47] Hezel, A.F., Kimmelman, A.C., Stanger, B.Z., Bardeesy, N., Depinho, R.A., Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20 (2006), 1218–1249, 10.1101/gad.1415606 20/10/1218 [pii].
48. [48] Acosta, J.C., O'Loghlen, A., Banito, A., Raguz, S., Gil, J., Control of senescence by CXCR2 and its ligands. Cell Cycle 7 (2008), 2956–2959 doi:6780 [pii].
49. [49] Acosta, J.C., et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133 (2008), 1006–1018, 10.1016/j.cell.2008.03.038S0092-8674(08)00619-3 [pii].
50. [50] Kuilman, T., et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133 (2008), 1019–1031, 10.1016/j.cell.2008.03.039S0092-8674(08)00620-X [pii].
51. [51] Tachibana, S., et al. Interleukin-6 is required for cell cycle arrest and activation of DNA repair enzymes after partial hepatectomy in mice. Cell Biosci., 4, 2014, 6, 10.1186/2045-3701-4-62045-3701-4-6 [pii].
52. [52] Yu, H., Pardoll, D., Jove, R., STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9 (2009), 798–809, 10.1038/nrc2734.
53. [53] Varghese, J.N., et al. Structure of the extracellular domains of the human interleukin-6 receptor alpha-chain. Proc. Natl. Acad. Sci. USA 99 (2002), 15959–15964, 10.1073/pnas.232432399.
54. [54] Imada, K., Leonard, W.J., The Jak-STAT pathway. Mol. Immunol. 37 (2000), 1–11.
55. [55] Dunn, G.P., Sheehan, K.C., Old, L.J., Schreiber, R.D., IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res. 65 (2005), 3447–3453, 10.1158/0008-5472.CAN-04-4316.
56. [56] Gu, L., et al. Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr. Relat. Cancer 17 (2010), 481–493, 10.1677/ERC-09-0328.
57. [57] Gao, A.C., Zhu, Y., Stat5a/b in prostate cancer metastasis. Am. J. Pathol. 185 (2015), 2351–2353, 10.1016/j.ajpath.2015.06.002.
58. [58] De Vita, F., et al. Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol. Rep. 5 (1998), 649–652.
59. [59] Blay, J.Y., et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 52 (1992), 3317–3322.
60. [60] Nakashima, J., et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin. Cancer Res. 6 (2000), 2702–2706.
61. [61] Giri, D., Ozen, M., Ittmann, M., Interleukin-6 is an autocrine growth factor in human prostate cancer. Am. J. Pathol. 159 (2001), 2159–2165, 10.1016/S0002-9440(10)63067-2.
62. [62] Hobisch, A., et al. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J. Pathol. 191 (2000), 239–244, 10.1002/1096-9896(2000)9999:9999<::AID-PATH633>3.0.CO;2-X.
63. [63] Azare, J., et al. Stat3 mediates expression of autotaxin in breast cancer. PLoS ONE, 6, 2011, e27851, 10.1371/journal.pone.0027851.
64. [64] Miyoshi, K., et al. Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor. J. Invest. Dermatol. 131 (2011), 108–117, 10.1038/jid.2010.255.
65. [65] Pardanani, A., et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 1 (2015), 643–651, 10.1001/jamaoncol.2015.1590.
66. [66] Pemmaraju, N., et al. A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin. Lymphoma Myeloma Leuk. 15 (2015), 171–176, 10.1016/j.clml.2014.08.003.
67. [67] Fizazi, K., et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur. J. Cancer 48 (2012), 85–93, 10.1016/j.ejca.2011.10.014S0959-8049(11)00821-5 [pii].
68. [68] Bishop, J.L., Thaper, D., Zoubeidi, A., The multifaceted roles of STAT3 signaling in the progression of prostate cancer. Cancers (Basel) 6 (2014), 829–859, 10.3390/cancers6020829.
69. [69] Karkera, J., et al. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate 71 (2011), 1455–1465, 10.1002/pros.21362.
70. [70] Dorff, T.B., et al. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin. Cancer Res. 16 (2010), 3028–3034, 10.1158/1078-0432.CCR-09-31221078-0432.CCR-09-3122 [pii].
71. [71] Hudes, G., et al. A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Invest. New Drugs 31 (2013), 669–676, 10.1007/s10637-012-9857-z.
72. [72] Egan, D.F., et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331 (2011), 456–461, 10.1126/science.1196371science.1196371 [pii].
73. [73] Taylor, B.S., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18 (2010), 11–22, 10.1016/j.ccr.2010.05.026.
74. [74] Wanjala, J., et al. Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling. Mol. Cancer Ther. 14 (2015), 278–288, 10.1158/1535-7163.MCT-14-0542-T.
75. [75] Grasso, C.S., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487 (2012), 239–243, 10.1038/nature11125.
76. [76] Pencik, J., et al. STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nat. Commun., 6, 2015, 7736, 10.1038/ncomms8736.
77. [77] Culig, Z., Pencik, J., Merkel, O., Kenner, L., Breaking a paradigm: IL-6/STAT3 signaling suppresses metastatic prostate cancer upon ARF expression. Mol. Cell. Oncol., 3, 2016, e1090048, 10.1080/23723556.2015.1090048.
78. [78] Pencik, J., Wiebringhaus, R., Susani, M., Culig, Z., Kenner, L., IL-6/STAT3/ARF: the guardians of senescence, cancer progression and metastasis in prostate cancer. Swiss Med. Wkly., 145, 2015, w14215, 10.4414/smw.2015.14215.
79. [79] Xiong, Y., et al. STAT3regulated long noncoding RNAs lnc7SK and lncIGF2AS promote hepatitis C virus replication. Mol. Med. Rep. 12 (2015), 6738–6744, 10.3892/mmr.2015.4278.
80. [80] Prensner, J.R., et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat. Genet. 45 (2013), 1392–1398, 10.1038/ng.2771.
81. [81] Weiss, M., Plass, C., Gerhauser, C., Role of lncRNAs in prostate cancer development and progression. Biol. Chem. 395 (2014), 1275–1290, 10.1515/hsz-2014-0201.
82. [82] Overhoff, M.G., et al. Cellular senescence mediated by p16INK4A-coupled miRNA pathways. Nucleic Acids Res. 42 (2014), 1606–1618, 10.1093/nar/gkt1096.
83. [83] Ghoreschi, K., Laurence, A., O'Shea, J.J., Janus kinases in immune cell signaling. Immunol. Rev. 228 (2009), 273–287, 10.1111/j.1600-065X.2008.00754.x.
84. [84] Witthuhn, B.A., et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 74 (1993), 227–236.
85. [85] Rodig, S.J., et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93 (1998), 373–383.
86. [86] Buckley, R.H., Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu. Rev. Immunol. 22 (2004), 625–655, 10.1146/annurev.immunol.22.012703.104614.
87. [87] Karaghiosoff, M., et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity 13 (2000), 549–560.
88. [88] Durbin, J.E., Hackenmiller, R., Simon, M.C., Levy, D.E., Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell 84 (1996), 443–450.
89. [89] Mathur, A.N., et al. Stat3 and Stat4 direct development of IL-17-secreting Th cells. J. Immunol. 178 (2007), 4901–4907.
90. [90] Chen, Z., et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc. Natl. Acad. Sci. USA 103 (2006), 8137–8142, 10.1073/pnas.0600666103.
91. [91] Zhu, J., Yamane, H., Paul, W.E., Differentiation of effector CD4 T cell populations (∗). Annu. Rev. Immunol. 28 (2010), 445–489, 10.1146/annurev-immunol-030409-101212.
92. [92] Kaplan, M.H., Sun, Y.L., Hoey, T., Grusby, M.J., Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 382 (1996), 174–177, 10.1038/382174a0.
93. [93] Zhu, J., Guo, L., Watson, C.J., Hu-Li, J., Paul, W.E., Stat6 is necessary and sufficient for IL-4’s role in Th2 differentiation and cell expansion. J. Immunol. 166 (2001), 7276–7281.
94. [94] Yao, Z., et al. Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 109 (2007), 4368–4375, 10.1182/blood-2006-11-055756.
95. [95] Nivarthi, H., Friedbichler, K., Moriggl, R., Decker, Thomas, Müller, Mathias, (eds.) Jak-Stat Signaling: From Basics to Disease, 2012, Springer, Vienna, 153–167.
96. [96] Yao, Z., et al. Stat5a/b are essential for normal lymphoid development and differentiation. Proc. Natl. Acad. Sci. USA 103 (2006), 1000–1005, 10.1073/pnas.0507350103.
97. [97] Kelly, J., et al. A role for Stat5 in CD8+ T cell homeostasis. J. Immunol. 170 (2003), 210–217.
98. [98] Migone, T.S., et al. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science 269 (1995), 79–81.
99. [99] Weber-Nordt, R.M., et al. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88 (1996), 809–816.
100. [100] Tortolani, P.J., et al. Regulation of JAK3 expression and activation in human B cells and B cell malignancies. J. Immunol. 155 (1995), 5220–5226.
101. [101] James, C., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005), 1144–1148, 10.1038/nature03546.
102. [102] Walters, D.K., et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 10 (2006), 65–75, 10.1016/j.ccr.2006.06.002.
103. [103] Flex, E., et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J. Exp. Med. 205 (2008), 751–758, 10.1084/jem.20072182.
104. [104] Mullighan, C.G., et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 106 (2009), 9414–9418, 10.1073/pnas.0811761106.
105. [105] Zl, W., Yq, S., Yf, S., Zhu, J., High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J. Hematol. Oncol. 4 (2011), 1–6, 10.1186/1756-8722-4-31.
106. [106] Ding, B.B., et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111 (2008), 1515–1523, 10.1182/blood-2007-04-087734.
107. [107] Hazan-Halevy, I., et al. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood 115 (2010), 2852–2863, 10.1182/blood-2009-10-230060.
108. [108] Koskela, H.L., et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. New England J. Med. 366 (2012), 1905–1913, 10.1056/NEJMoa1114885.
109. [109] Fasan, A., et al. STAT3 mutations are highly specific for large granular lymphocytic leukemia. Leukemia 27 (2013), 1598–1600, 10.1038/leu.2012.350.
110. [110] Jerez, A., et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood 120 (2012), 3048–3057, 10.1182/blood-2012-06-435297.
111. [111] Ohgami, R.S., et al. STAT3 mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia. Leukemia 27 (2013), 2244–2247, 10.1038/leu.2013.104.
112. [112] Kristensen, T., et al. Clinical relevance of sensitive and quantitative STAT3 mutation analysis using next-generation sequencing in T-cell large granular lymphocytic leukemia. J. Mol. Diagnostics: JMD 16 (2014), 382–392, 10.1016/j.jmoldx.2014.02.005.
113. [113] Ohgami, R.S., Ma, L., Monabati, A., Zehnder, J.L., Arber, D.A., STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression. Haematologica 99 (2014), e105–e107, 10.3324/haematol.2013.101543.
114. [114] Loughran, T.P. Jr., et al. Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia 29 (2015), 886–894, 10.1038/leu.2014.298.
115. [115] Couronne, L., et al. STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica 98 (2013), 1748–1752, 10.3324/haematol.2013.085068.
116. [116] Bamford, S., et al. The COSMIC (catalogue of somatic mutations in cancer) database and website. Br. J. Cancer 91 (2004), 355–358, 10.1038/sj.bjc.6601894.
117. [117] Nicolae, A., et al. Frequent STAT5B mutations in gammadelta hepatosplenic T-cell lymphomas. Leukemia 28 (2014), 2244–2248, 10.1038/leu.2014.200.
118. [118] Jerez, A., et al. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. Blood 122 (2013), 2453–2459, 10.1182/blood-2013-04-494930.
119. [119] Morin, R.D., et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476 (2011), 298–303, 10.1038/nature10351.
120. [120] Odejide, O., et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 123 (2014), 1293–1296, 10.1182/blood-2013-10-531509.
121. [121] Nicolae, A., et al. Frequent STAT5B mutations in gammadelta hepatosplenic T-cell lymphomas. Leukemia, 2014, 10.1038/leu.2014.200.
122. [122] Rajala, H.L., et al. Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood 121 (2013), 4541–4550, 10.1182/blood-2012-12-474577.
123. [123] Kontro, M., et al. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. Leukemia 28 (2014), 1738–1742, 10.1038/leu.2014.89.
124. [124] Bandapalli, O.R., et al. The activating STAT5B N642H mutation is a common abnormality in pediatric T-cell acute lymphoblastic leukemia and confers a higher risk of relapse. Haematologica, 2014, 10.3324/haematol.2014.104992.
125. [125] Kiel, M.J., et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood, 2014, 10.1182/blood-2014-03-559542.
126. [126] Ariyoshi, K., et al. Constitutive activation of STAT5 by a point mutation in the SH2 domain. J. Biol. Chem. 275 (2000), 24407–24413, 10.1074/jbc.M909771199.
127. [127] Onishi, M., et al. Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation. Mol. Cell. Biol. 18 (1998), 3871–3879.
128. [128] Burchill, M.A., et al. Distinct effects of STAT5 activation on CD4+ and CD8+ T cell homeostasis: development of CD4+CD25+ regulatory T cells versus CD8+ memory T cells. J. Immunol. 171 (2003), 5853–5864.
129. [129] Goetz, C.A., Harmon, I.R., O'Neil, J.J., Burchill, M.A., Farrar, M.A., STAT5 activation underlies IL7 receptor-dependent B cell development. J. Immunol. 172 (2004), 4770–4778.
130. [130] Mikita, T., Daniel, C., Wu, P., Schindler, U., Mutational analysis of the STAT6 SH2 domain. J. Biol. Chem. 273 (1998), 17634–17642.
131. [131] Pasqualucci, L., et al. Genetics of follicular lymphoma transformation. Cell Rep. 6 (2014), 130–140, 10.1016/j.celrep.2013.12.027.
132. [132] Morin, R.D., et al. Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas. Clin. Cancer Res.: Official J. Am. Assoc. Cancer Res. 22 (2016), 2290–2300, 10.1158/1078-0432.CCR-15-2123.
133. [133] Buchert, M., Burns, C.J., Ernst, M., Targeting JAK kinase in solid tumors: emerging opportunities and challenges. Oncogene 35 (2016), 939–951, 10.1038/onc.2015.150.
134. [134] Villarino, A., et al. Decker, Thomas, Müller, Mathias, (eds.) Jak-Stat Signaling: From Basics to Disease, 2012, Springer, Vienna, 205–237.
135. [135] Flanagan, M.E., et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J. Med. Chem. 53 (2010), 8468–8484, 10.1021/jm1004286.
136. [136] Curtis, J.R., et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann. Rheum. Dis. 75 (2016), 831–841, 10.1136/annrheumdis-2014-205847.
137. [137] Hexner, E.O., et al. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111 (2008), 5663–5671, 10.1182/blood-2007-04-083402.
138. [138] Schaap, N.P., et al. Efficacy and safety of fedratinib (SAR302503/TG101348) in patients with intermediate- or high-risk myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF previously treated with ruxolitinib: interim results from a phase II study (JAKARTA-2). Blood, 122, 2013, 661.
139. [139] Barriocanal, M., Carnero, E., Segura, V., Fortes, P., Long non-coding RNA BST2/BISPR is induced by IFN and regulates the expression of the antiviral factor tetherin. Front. Immunol., 5, 2014, 655, 10.3389/fimmu.2014.00655.
140. [140] Furqan, M., et al. STAT inhibitors for cancer therapy. J. Hematol. Oncol., 6, 2013, 90, 10.1186/1756-8722-6-90.
141. [141] Hong, D., et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci. Trans. Med., 7, 2015, 314ra185, 10.1126/scitranslmed.aac5272.
142. [142] Page, B.D., et al. Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity. J. Med. Chem. 55 (2012), 1047–1055, 10.1021/jm200720n.
143. [143] Nelson, E.A., et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 117 (2011), 3421–3429, 10.1182/blood-2009-11-255232.
144. [144] Anderson, J.L., et al. Phosphoproteomic profiling reveals IL6-mediated paracrine signaling within the Ewing sarcoma family of tumors. Mol. Cancer Res.: MCR 12 (2014), 1740–1754, 10.1158/1541-7786.MCR-14-0159.
145. [145] Minas, T.Z., et al. YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model. Oncotarget 6 (2015), 37678–37694, 10.18632/oncotarget.5520.
146. [146] Minas, T.Z., et al. Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. Oncotarget, 2016, 10.18632/oncotarget.9388.
147. [147] David, E., et al. Oncostatin M is a growth factor for Ewing sarcoma. Am. J. Pathol. 181 (2012), 1782–1795, 10.1016/j.ajpath.2012.07.023.
148. [148] Lin, E.Y., Pollard, J.W., Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res. 67 (2007), 5064–5066, 10.1158/0008-5472.CAN-07-0912.
149. [149] Noy, R., Pollard, J.W., Tumor-associated macrophages: from mechanisms to therapy. Immunity 41 (2014), 49–61, 10.1016/j.immuni.2014.06.010.
150. [150] Fujiwara, T., et al. Macrophage infiltration predicts a poor prognosis for human Ewing sarcoma. Am. J. Pathol. 179 (2011), 1157–1170, 10.1016/j.ajpath.2011.05.034.
151. [151] Zhang, Z., et al. Let-7a functions as a tumor suppressor in Ewing's sarcoma cell lines partly by targeting cyclin-dependent kinase 6. DNA Cell Biol. 33 (2014), 136–147, 10.1089/dna.2013.2179.
152. [152] Marques Howarth, M., et al. Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis. J. Clin. Invest. 124 (2014), 5275–5290, 10.1172/JCI72124.
153. [153] Sun, X., et al. DICER1 regulated let-7 expression levels in p53-induced cancer repression requires cyclin D1. J. Cell Mol. Med. 19 (2015), 1357–1365, 10.1111/jcmm.12522.
154. [154] Zhang, Z., et al. Let-7a suppresses macrophage infiltrations and malignant phenotype of Ewing sarcoma via STAT3/NF-kappaB positive regulatory circuit. Cancer Lett. 374 (2016), 192–201, 10.1016/j.canlet.2016.02.027.
155. [155] Sampson, V.B., et al. Vorinostat enhances cytotoxicity of SN-38 and temozolomide in Ewing sarcoma cells and activates STAT3/AKT/MAPK pathways. PLoS ONE, 10, 2015, e0142704, 10.1371/journal.pone.0142704.
156. [156] Salas, S., et al. Correlation between ERK1 and STAT3 expression and chemoresistance in patients with conventional osteosarcoma. BMC Cancer, 14, 2014, 606, 10.1186/1471-2407-14-606.
157. [157] Liu, L.H., et al. MiR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3. Biochem. Biophys. Res. Commun. 416 (2011), 31–38, 10.1016/j.bbrc.2011.10.117.
158. [158] Wang, X., Goldstein, D., Crowe, P.J., Yang, J.L., Impact of STAT3 inhibition on survival of osteosarcoma cell lines. Anticancer Res. 34 (2014), 6537–6545.
159. [159] Ilisso, C.P., et al. S-Adenosylmethionine affects ERK1/2 and Stat3 pathways and induces apotosis in osteosarcoma cells. J. Cell. Physiol. 231 (2016), 428–435, 10.1002/jcp.25089.
160. [160] Goldblum, J.R., An approach to pleomorphic sarcomas: can we subclassify, and does it matter?. Mod. Pathol. 27:Suppl. 1 (2014), S39–S46, 10.1038/modpathol.2013.174.
161. [161] Gadd, S., et al. Mediators of receptor tyrosine kinase activation in infantile fibrosarcoma: a Children's Oncology Group study. J. Pathol. 228 (2012), 119–130, 10.1002/path.4010.
162. [162] Mendenhall, W.M., Mendenhall, C.M., Werning, J.W., Reith, J.D., Mendenhall, N.P., Cutaneous angiosarcoma. Am. J. Clin. Oncol. 29 (2006), 524–528, 10.1097/01.coc.0000227544.01779.52.
163. [163] Chen, S.Y., et al. Overexpression of phosphorylated-ATF2 and STAT3 in cutaneous angiosarcoma and pyogenic granuloma. J. Cutan. Pathol. 35 (2008), 722–730.
164. [164] Antonescu, C.R., et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin. Cancer Research: Official J. Am. Assoc. Cancer Res. 7 (2001), 3977–3987.
165. [165] Nabeshima, A., et al. Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/Akt pathways. Br. J. Cancer 112 (2015), 547–555, 10.1038/bjc.2014.637.
166. [166] Carninci, P., et al. The transcriptional landscape of the mammalian genome. Science 309 (2005), 1559–1563, 10.1126/science.1112014.
167. [167] Wahlestedt, C., Targeting long non-coding RNA to therapeutically upregulate gene expression. Nat. Rev. Drug Discovery 12 (2013), 433–446, 10.1038/nrd4018.
168. [168] Gutschner, T., Diederichs, S., The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 9 (2012), 703–719, 10.4161/rna.20481.
169. [169] Valastyan, S., et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137 (2009), 1032–1046, 10.1016/j.cell.2009.03.047.
170. [170] Ma, L., et al. MiR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 12 (2010), 247–256, 10.1038/ncb2024.
171. ∗ repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat. Cell Biol. 15 (2013), 284–294, 10.1038/ncb2690.
172. [172] Cabili, M.N., et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 25 (2011), 1915–1927, 10.1101/gad.17446611.
173. [173] Sigova, A.A., et al. Divergent transcription of long noncoding RNA/mRNA gene pairs in embryonic stem cells. Proc. Natl. Acad. Sci. USA 110 (2013), 2876–2881, 10.1073/pnas.1221904110.
174. [174] Hangauer, M.J., Vaughn, I.W., McManus, M.T., Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs. PLoS Genet., 9, 2013, e1003569, 10.1371/journal.pgen.1003569.
175. [175] Kornienko, A.E., Guenzl, P.M., Barlow, D.P., Pauler, F.M., Gene regulation by the act of long non-coding RNA transcription. BMC Biol., 11, 2013, 59, 10.1186/1741-7007-11-59.
176. [176] Geisler, S., Coller, J., RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat. Rev. Mol. Cell Biol. 14 (2013), 699–712, 10.1038/nrm3679.
177. [177] Kim, D.H., et al. Single-cell transcriptome analysis reveals dynamic changes in lncRNA expression during reprogramming. Cell Stem Cell 16 (2015), 88–101, 10.1016/j.stem.2014.11.005.
178. [178] Gupta, R.A., et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464 (2010), 1071–1076, 10.1038/nature08975.
179. [179] Guttman, M., et al. LincRNAs act in the circuitry controlling pluripotency and differentiation. Nature 477 (2011), 295–300, 10.1038/nature10398.
180. [180] Schmidt, L.H., et al. The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth. J. Thoracic Oncol.: Official Publ. Int. Assoc. Study Lung Cancer 6 (2011), 1984–1992, 10.1097/JTO.0b013e3182307eac.
181. [181] Bartel, D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004), 281–297.
182. [182] Boosani, C.S., Agrawal, D.K., Methylation and microRNA-mediated epigenetic regulation of SOCS3. Mol. Biol. Rep. 42 (2015), 853–872, 10.1007/s11033-015-3860-3.
183. [183] Jiang, S., et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 70 (2010), 3119–3127, 10.1158/0008-5472.CAN-09-4250.
184. [184] Merkel, O., et al. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. J. Pathol. 236 (2015), 445–456, 10.1002/path.4539.
185. [185] Che, S., et al. MiR-30 overexpression promotes glioma stem cells by regulating Jak/STAT3 signaling pathway. Tumour Biol. 36 (2015), 6805–6811, 10.1007/s13277-015-3400-8.
186. [186] Collins, A.S., McCoy, C.E., Lloyd, A.T., O'Farrelly, C., Stevenson, N.J., MiR-19a: an effective regulator of SOCS3 and enhancer of JAK-STAT signalling. PLoS ONE, 8, 2013, e69090, 10.1371/journal.pone.0069090.
187. [187] Cheng, X., et al. MiR-19b downregulates intestinal SOCS3 to reduce intestinal inflammation in Crohn's disease. Sci. Rep., 5, 2015, 10397, 10.1038/srep10397.
188. [188] Kneitz, B., et al. Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. Cancer Res. 74 (2014), 2591–2603, 10.1158/0008-5472.CAN-13-1606.
189. [189] Zhuang, G., et al. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J. 31 (2012), 3513–3523, 10.1038/emboj.2012.183.
190. [190] Wu, W., et al. MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis. Br. J. Cancer 108 (2013), 653–661, 10.1038/bjc.2012.587.
191. [191] Hou, B.H., et al. MiR-216a may inhibit pancreatic tumor growth by targeting JAK2. FEBS Lett. 589 (2015), 2224–2232, 10.1016/j.febslet.2015.06.036.
192. [192] Aghaee-Bakhtiari, S.H., et al. MAPK and JAK/STAT pathways targeted by miR-23a and miR-23b in prostate cancer: computational and in vitro approaches. Tumour Biol. 36 (2015), 4203–4212, 10.1007/s13277-015-3057-3.
193. [193] Harrow, J., et al. GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res. 22 (2012), 1760–1774, 10.1101/gr.135350.111.
194. [194] Ulitsky, I., Bartel, D.P., LincRNAs: genomics, evolution, and mechanisms. Cell 154 (2013), 26–46, 10.1016/j.cell.2013.06.020.
195. [195] Johnsson, P., Lipovich, L., Grander, D., Morris, K.V., Evolutionary conservation of long non-coding RNAs; sequence, structure, function. Biochim. Biophys. Acta 1840 (2014), 1063–1071, 10.1016/j.bbagen.2013.10.035.
196. [196] Ji, P., et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 22 (2003), 8031–8041, 10.1038/sj.onc.1206928.
197. [197] Huarte, M., et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell 142 (2010), 409–419, 10.1016/j.cell.2010.06.040.
198. [198] Yang, L., et al. LncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature 500 (2013), 598–602, 10.1038/nature12451.
199. [199] Yildirim, E., et al. Xist RNA is a potent suppressor of hematologic cancer in mice. Cell 152 (2013), 727–742, 10.1016/j.cell.2013.01.034.
200. [200] Huang, G., et al. The long noncoding RNA CASC2 functions as a competing endogenous RNA by sponging miR-18a in colorectal cancer. Sci. Rep., 6, 2016, 26524, 10.1038/srep26524.
201. [201] Wang, P., et al. The STAT3-binding long noncoding RNA lnc-DC controls human dendritic cell differentiation. Science 344 (2014), 310–313, 10.1126/science.1251456.
202. [202] Kambara, H., et al. Negative regulation of the interferon response by an interferon-induced long non-coding RNA. Nucleic Acids Res. 42 (2014), 10668–10680, 10.1093/nar/gku713.
203. [203] Westermann, A.J., et al. Dual RNA-seq unveils noncoding RNA functions in host-pathogen interactions. Nature 529 (2016), 496–501, 10.1038/nature16547.